Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-09-09

Clinical Trial Update: Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating inhaled nitric oxide to prevent or treat ischemia-reperfusion lung injury in lung transplant patients was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Inhaled Nitric Oxide (INOmax) (nitric oxide)

Snippet

Sponsor: Mallinckrodt | Conditions: Ischemia-Reperfusion Injury | Phase 3 | Status: TERMINATED